Clinical utility of expanded carrier screening in the preconception and prenatal population: A Chinese cohort study.

Clin Chim Acta

The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200030, China; Shanghai Key Laboratory of Embryo Original Diseases, Shanghai 200030, China; Institute of Birth Defects and Rare Diseases, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address:

Published: January 2025

AI Article Synopsis

  • The study assessed the effectiveness of expanded carrier screening (ECS) in Chinese preconception and prenatal populations by analyzing carrier frequencies and effects on at-risk couples (ARCs).
  • Out of 6,298 individuals screened, 42.4% were found to be carriers of harmful genetic variants, with 2.22% identified as ARCs, primarily for conditions like GJB2-related deafness and Duchenne muscular dystrophy.
  • The findings emphasize the clinical value of ECS, showing that a significant percentage of ARCs made important reproductive choices based on the results, supporting the development of a tailored ECS panel for the Chinese population.

Article Abstract

Objectives: To evaluate the clinical utility of expanded carrier screening (ECS) in Chinese preconception and prenatal populations, focusing on carrier frequency and the impact on at-risk couples (ARCs).

Methods: Data from 6,298 Chinese individuals from 4,420 families who underwent a 149-gene ECS panel at a single center were analyzed. The prevalence of positive carriers and ARCs was determined, with follow-up on reproductive decisions and pregnancy outcomes for ARCs.

Results: Of the individuals screened, 2,673 (42.4 %) were carriers of at least one pathogenic or likely pathogenic variant, and 98 (2.22 %) ARCs were identified. GJB2-related deafness and Duchenne muscular dystrophy were the most common autosomal recessive (AR) and X-linked disorders. Screening the top 11 (gene carrier rate [GCR] ≥ 1/100), 22 (GCR ≥ 1/200), and 41 (GCR ≥ 1/331) AR genes could identify 53.5 %, 67.9 %, and 81.3 % of variants, respectively. The corresponding ratios for identified ARCs were 90.4 %, 94.0 %, and 100 %. Follow-up data from 80 ARCs indicated that 75.0 % (60/80) took significant action based on the ECS results. Additionally, four families (3.5 %, 4/115) were identified at risk for a second disease unrelated to their initial family monogenic history.

Conclusions: This study, representing the largest cohort of a moderate-sized ECS panel test in the Chinese population, demonstrates the clinical utility of ECS in both healthy individuals and those with a family history of monogenic disorders. The data obtained provide valuable insights for developing a Chinese-specific ECS panel. Tailored approaches are critical for wider adoption and successful routine application of ECS.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cca.2024.120017DOI Listing

Publication Analysis

Top Keywords

clinical utility
12
ecs panel
12
utility expanded
8
expanded carrier
8
carrier screening
8
preconception prenatal
8
ecs
7
carrier
4
screening preconception
4
prenatal population
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!